Literature DB >> 1347057

Immunologic markers of clinical evolution in children recently infected with Leishmania donovani chagasi.

E M Carvalho1, A Barral, D Pedral-Sampaio, M Barral-Netto, R Badaró, H Rocha, W D Johnson.   

Abstract

The study attempted to identify immunologic markers for progression of Leishmania donovani chagasi infection to disease in children in an area endemic for visceral leishmaniasis (VL). [3H]thymidine uptake of lymphocytes stimulated with L. donovani chagasi antigen from children with asymptomatic infection (25,286 +/- 11,648) and from children with self-healing subclinical infection (15,511 +/- 4681) was greater (P = .001) than that observed with lymphocytes from children who progressed to classic VL (4811 +/- 2984). The interferon-gamma (IFN-gamma) levels from asymptomatic and subclinically infected children (74 +/- 90 units/ml) were higher (P = .02) than those observed in children who progressed to VL (7 +/- 8 units/ml). Absence of lymphocyte blastogenesis and IFN-gamma production were associated with progression of infection to classic VL. In the presence of these markers, children should be closely followed to identify signs and symptoms that would permit early initiation of therapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1347057     DOI: 10.1093/infdis/165.3.535

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  56 in total

Review 1.  Clinical and experimental advances in treatment of visceral leishmaniasis.

Authors:  H W Murray
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

2.  Soluble CD26/CD30 levels in visceral leishmaniasis: markers of disease activity.

Authors:  S Ajdary; F Riazi-Rad; R Jafari-Shakib; M Mohebbali
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

3.  HLA-DR Class II expression on myeloid and lymphoid cells in relation to HLA-DRB1 as a genetic risk factor for visceral leishmaniasis.

Authors:  Bhawana Singh; Michaela Fakiola; Medhavi Sudarshan; Joyce Oommen; Siddharth Sankar Singh; Shyam Sundar; Jenefer M Blackwell
Journal:  Immunology       Date:  2018-11-22       Impact factor: 7.397

4.  Neurological manifestations in a patient with visceral leishmaniasis.

Authors:  B Karak; R K Garg; S Misra; A M Sharma
Journal:  Postgrad Med J       Date:  1998-07       Impact factor: 2.401

5.  Immune responses of Iranian patients with visceral leishmaniasis and recovered individuals to LCR1 of Leishmania infantum.

Authors:  Hamid M Niknam; Firoozeh Abrishami; Mohammad Doroudian; Mosayeb Rostamian; Maryam Moradi; Vahid Khaze; Davood Iravani
Journal:  Clin Vaccine Immunol       Date:  2014-02-05

6.  Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy.

Authors:  Rafael de La Rosa; Juan A Pineda; Juan Delgado; Juan Macías; Francisco Morillas; José A Mira; Armando Sánchez-Quijano; Manuel Leal; Eduardo Lissen
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

7.  Recombinant leishmania antigens for serodiagnosis of visceral leishmaniasis.

Authors:  S Passos; L P Carvalho; G Orge; S M Jerônimo; G Bezerra; M Soto; C Alonso; E M Carvalho
Journal:  Clin Diagn Lab Immunol       Date:  2005-10

8.  Reduced infectivity of a Leishmania donovani biopterin transporter genetic mutant and its use as an attenuated strain for vaccination.

Authors:  Barbara Papadopoulou; Gaétan Roy; Marie Breton; Christoph Kündig; Carole Dumas; Isabelle Fillion; Ajay K Singh; Martin Olivier; Marc Ouellette
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

9.  Asymptomatic Leishmania infection: a new challenge for Leishmania control.

Authors:  Om Prakash Singh; Epco Hasker; David Sacks; Marleen Boelaert; Shyam Sundar
Journal:  Clin Infect Dis       Date:  2014-02-27       Impact factor: 9.079

10.  Human immunodeficiency virus and leishmaniasis.

Authors:  Navid Ezra; Maria Teresa Ochoa; Noah Craft
Journal:  J Glob Infect Dis       Date:  2010-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.